MediWound (MDWD)
(Delayed Data from NSDQ)
$17.69 USD
+0.08 (0.45%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $17.73 +0.04 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
MediWound Ltd. [MDWD]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: MediWound Ltd.
Industry: Medical - Drugs
Molnlycke Investment Validates EscharEx; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Company: MediWound Ltd.
Industry: Medical - Drugs
Strong Adoption Following NexoBrid Launches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
EscharEx Demonstrated Paradigm-shifting Potential in VLU Debridement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: MediWound Ltd.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: MediWound Ltd.
Industry: Medical - Drugs
NexoBrid to Drive Growth in 2025 and Beyond; New $28 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for MDWD 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: MediWound Ltd.
Industry: Medical - Drugs
Demand for NexoBrid Increased Worldwide; Phase 3 Study of EscharEx to Enroll in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
FDA Clears NexoBrid for Commercialization; New PT of $26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Launch of NexoBrid and Initiation of Pivotal Phase 3 of EscharEx Expected in 1Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Expanded Manufacturing Facility to Sustain NexoBrid Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Company: MediWound Ltd.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: MediWound Ltd.
Industry: Medical - Drugs
NexoBrid Approved; PT Adjusted to $23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
NexoBrid BLA Under Review; EscharEx to Enter Pivotal Phase 3; Lower PT to $5.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Potential NexoBrid Approval in 2023; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Nuggets From KOL Event on EscharEx; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
EscharEx Continues to Achieve Positive Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: MediWound Ltd.
Industry: Medical - Drugs
Robust EscharEx Phase 2 Data; Change of Guard Not Impactful; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S